APTATARGETS S.L
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
APTATARGETS S.L - overview
Established
2015
Location
Madrid, -, Spain
Primary Industry
Biotechnology
About
AptaTargets is a clinical-stage biotechnology company focused on developing therapeutic aptamers, particularly ApTOLL, aimed at treating acute inflammatory conditions such as stroke and myocardial infarction. Founded in 2015, AptaTargets S. L is based in Madrid, Spain, where it focuses on the development of its lead product, ApTOLL, an immune modulator targeting TLR4. The company's recent funding round, a Series B completed in October 2020, raised EUR 5 million from investors including the Centre for Technological & Industrial Development and Inveready Asset Management.
The company has completed a total of 5 deals to date. AptaTargets specializes in therapeutic aptamers, focusing on ApTOLL, which modulates the immune response by targeting TLR4 to reduce brain damage from acute ischemic stroke. ApTOLL also has potential applications for other acute conditions such as intracerebral hemorrhage and myocardial infarction. The company is advancing ApTOLL through clinical trials and aims to expand its therapeutic portfolio internationally.
In the most recent year, 2023, AptaTargets reported revenue of EUR 2,170,284. 80 with an EBITDA of EUR -5,720. 50, primarily generated through partnerships and potential agreements with pharmaceutical companies involved in the development and commercialization of ApTOLL. AptaTargets plans to utilize proceeds from its EUR 5 million Series B funding round to advance ApTOLL through clinical trials, with aspirations for market entry in the coming years.
The company is exploring expansion into European and global markets, targeting regions that require innovative treatments for acute inflammatory conditions, leveraging its clinical data to form strategic partnerships with healthcare institutions and pharmaceutical collaborators.
Current Investors
Inveready Asset Management, Caixa Capital Risc, Spain Ministry of Economy and Competitiveness
Primary Industry
Biotechnology
Sub Industries
Biotechnology, Pharmaceutical Research & Development
Website
www.aptatargets.com
Company Stage
Series B
Total Amount Raised
Subscriber access only
APTATARGETS S.L - timeline of key events
APTATARGETS S.L - financials
| Fiscal Year Ended | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | - | 393,377.8 | 1,197,076.3 | 1,879,835.7 | 1,921,334 | 1,649,720.9 | 1,844,849.8 | - | - | - |
| % Revenue Growth (YoY) | - | - | 204.3% | 57.0% | 2.2% | (14.1%) | 11.8% | - | - | - |
| EBITDA (USD) | (2,829) | 66,332.2 | 25,633.4 | 242,059.6 | 96,813.4 | 216,709.6 | 271,335.7 | - | - | - |
| Operating Income (USD) | (3,124) | 65,589.3 | 6,653.8 | 198,211.9 | 53,089.9 | 172,715.9 | 231,978 | - | - | - |
| Operating Margin | - | 16.7% | 0.6% | 10.5% | 2.8% | 10.5% | 12.6% | - | - | - |
| % EBITDA Margin | - | 16.9% | 2.1% | 12.9% | 5.0% | 13.1% | 14.7% | - | - | - |
| NET Income (USD) | (6,667.4) | 91,024.3 | (3,527.4) | 121,964.9 | (38,254.5) | 38,639.2 | 27,319 | - | - | - |
| % Net Margin | - | 23.1% | (0.3%) | 6.5% | (2.0%) | 2.3% | 1.5% | - | - | - |
APTATARGETS S.L - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.